• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Steady-state fluctuation and variability of betaxolol and atenolol plasma levels.

作者信息

Kunka R L, Wong Y Y, Andersen R L, Haack D G

机构信息

Corporate Medical and Scientific Affairs, G. D. Searle and Co., Skokie, Illinois.

出版信息

Ther Drug Monit. 1989 Sep;11(5):523-7.

PMID:2573178
Abstract

Twenty-four nonsmoking male volunteers took 50 mg atenolol or 10 mg betaxolol orally once a day for 9 days in a two-period, four-sequence, randomized, crossover study. Plasma concentrations reached steady state after day 5. Percent fluctuation in plasma concentration defined as (Cmax-Cmin)/Cavg (% fluctuation 1) was 97% on day 9 for betaxolol and 343% for atenolol; thus atenolol fluctuation was more than threefold that of betaxolol. A 10-fold difference in plasma level fluctuation was observed when fluctuation was defined as (Cmax-Cmin)/Cmin (% fluctuation 2). The intersubject variances for % fluctuation 1 and % fluctuation 2 were 4.1 and 85.5 times greater for atenolol than for betaxolol; these differences were marginally statistically significant for % fluctuation 1 and significant for % fluctuation 2. The intrasubject variabilities for area under the curve and plasma level fluctuations were statistically greater for atenolol than for betaxolol. Atenolol intrasubject variances were 25 and 271 times greater than for betaxolol for % fluctuation 1 and % fluctuation 2, respectively. Thus, betaxolol exhibited less fluctuation in plasma levels with substantially less intersubject and intrasubject variability. These factors would be expected to provide a more consistent therapeutic response and more dependable dosage adjustment.

摘要

相似文献

1
Steady-state fluctuation and variability of betaxolol and atenolol plasma levels.
Ther Drug Monit. 1989 Sep;11(5):523-7.
2
Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Blood Press Suppl. 1993;1:16-21.
3
[Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension].
Ann Cardiol Angeiol (Paris). 1987 Nov;36(9):487-93.
4
Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.单次给药后两种阿替洛尔片剂制剂在健康男性志愿者中的相对生物利用度。
Int J Clin Pharmacol Ther. 1997 Aug;35(8):324-8.
5
Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit.局部应用的β肾上腺素能拮抗剂在有色家兔体内的全身吸收途径
Exp Eye Res. 1993 Sep;57(3):341-9. doi: 10.1006/exer.1993.1133.
6
Effect of itraconazole on the pharmacokinetics of atenolol.伊曲康唑对阿替洛尔药代动力学的影响。
Basic Clin Pharmacol Toxicol. 2005 Dec;97(6):395-8. doi: 10.1111/j.1742-7843.2005.pto_223.x.
7
Bioequivalence study of generic atenolol tablets in healthy Thai volunteers.通用型阿替洛尔片在泰国健康志愿者中的生物等效性研究。
J Med Assoc Thai. 1999 Sep;82(9):907-14.
8
Effect of rifampicin on the pharmacokinetics of atenolol.利福平对阿替洛尔药代动力学的影响。
Basic Clin Pharmacol Toxicol. 2006 Jun;98(6):555-8. doi: 10.1111/j.1742-7843.2006.pto_379.x.
9
Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men.阿替洛尔对映体在12名中国健康男性中的药代动力学。
Zhongguo Yao Li Xue Bao. 1999 Apr;20(4):367-70.
10
Comparative pharmacokinetics of two brands of atenolol following a single oral administration.单次口服给药后两种品牌阿替洛尔的比较药代动力学
Int J Clin Pharmacol Ther. 1996 Oct;34(10):457-61.

引用本文的文献

1
Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension.心动过速:单纯性动脉高血压中的隐匿性心血管危险因素。
Cardiol J. 2020;27(6):857-867. doi: 10.5603/CJ.a2019.0021. Epub 2019 Feb 25.
2
Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension.联合α/β受体阻滞剂:一种治疗顽固性高血压但未得到充分应用的方法。
J Clin Hypertens (Greenwich). 2007 Sep;9(9):663-6. doi: 10.1111/j.1524-6175.2007.07225.x.
3
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
阿替洛尔:对其药理特性及在心血管疾病治疗应用的重新评估
Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007.